Jung‐Im Na
서울대학교 의예과 · 의학
Jung-Im Na 교수의 연구실은 피부색소질환, 특히 임신성 피부색소침착증(melasma)의 치료에 초점을 맞추고 있으며, 탈색제, 성장인자, 나노입자 캡슐화 기술을 활용한 신개념 외용제 개발에 주력하고 있습니다. 또한 외상 치유 촉진, 피부염증 조절, 미세한 지방 입자 기반 보습제 등 피부 건강 유지를 위한 다양한 피부질환 치료 전략을 연구하고 있습니다. 특히, 부작용이 적은 효과적인 치료제 개발을 목표로 하며, 임상적 실용성과 안전성을 고려한 약물 전달 시스템을 중심으로 연구를 진행하고 있습니다.
표시된 성과는 수집된 데이터 기준으로 산출되며, 일부 차이가 있을 수 있습니다.
TXA decreased epidermal pigmentation associated with melasma and also reversed melasma-related dermal changes, such as vessel number and increased numbers of mast cells.
Application of autologous PRP is an effective method for enhancing wound healing and reducing transient adverse effects after FxCR treatment.
Melanin is produced in melanocytes and stored in melanosomes, after which it is transferred to keratinocytes and, thus, determines skin color. Despite its beneficial sun-protective effects, abnormal accumulation of melanin results in esthetic problems. A range of topical hypopigmenting agents have been evaluated for their use in the treatment of pigmentary disorders with varying degrees of success. Hydroquinone (HQ), which competes with tyrosine, is the main ingredient in topical pharmacological
IAA PDT has therapeutic effects on acne via its antimicrobial activities, its sebum-reducing effect and through relieving follicular occlusion. It is a very simple and safe treatment option for acne.
The cream containing liposome-encapsulated 4nBR and RSV was shown to be effective and safe for the treatment of melasma with its effect appearing as early as 2 weeks.
Moisturizer containing lipid granules effectively controlled atopic dermatitis.
Since the outbreak of COVID-19 in December 2019, more than 4 million people have died worldwide. The global pandemic of COVID-19 has prompted each country to issue an emergency use authorization for COVID-19 vaccines. In South Korea, the Ministry of Food and Drug Safety authorized the administration of four vaccines: Pfizer-BioNTech (BNT162b2, New York, NY, USA), Moderna (mRNA-1273, Cambridge, MA, USA), Oxford–AstraZeneca (ChAdOx1, Cambridge, UK) and Johnson & Johnson’s Janssen (JNJ-78436735, Be
The synthetic data set in this diagnostic study was created using various AI technologies from internet images. A neural network trained on the created data set (CAN5600) performed better than the same network trained on preexisting data sets combined. Both the annotated (CAN5600 and LESION130k) and synthetic (GAN5000) data sets could be shared for AI training and consensus between physicians.
Angioblastoma usually develops in infancy or early childhood on the neck or upper trunk. It is known to be slowly progressive and benign in nature, but treatment guidelines have not yet been established. Spontaneous regression has been occasionally documented, and treatment with pulsed dye laser, excision, high-dose steroids, and interferon alpha have been successful in individual patients. Our patient experienced partial response to interferon alpha injection, and for further treatment, long-pu
<b>Background:</b> Scalp-related symptoms such as dandruff and itching are common with diverse underlying etiologies. We previously proposed a novel classification and scoring system for scalp conditions, called the scalp photographic index (SPI); it grades five scalp features using trichoscopic images with good reliability. However, it requires trained evaluators.<b>Aim:</b> To develop artificial intelligence (AI) algorithms for assessment of scalp conditions and to assess the feasibility of AI
SJW-PDT is a simple, safe, and effective treatment option for acne that is also beneficial for skin rejuvenation.
SPI is an objective, reproducible, and validated numeric system for classifying and scoring scalp conditions.
Childhood granulomatous periorificial dermatitis (CGPD) is a self-limiting skin condition characterized by papular eruptions around the mouth, nose and eyes of preadolescent children. We report two cases of intractable CGPD in which patients receiving growth hormone (GH) therapy showed persistent symptoms despite multiple treatment modalities. This association may suggest the role of GH in the pathogenesis of CGPD.
ClinicalTrials.gov Identifier: NCT05517824.